Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...
Please provide your email address to receive an email when new articles are posted on . Patients receiving triple combination COPD therapy had fewer exacerbations than patients receiving dual therapy.
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results